Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Niek Wijnen
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07312292CT.gov Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) | — | Recruiting | — | — | — |
NCT06584071CT.gov A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | — | Not Yet Recruiting | — | — | — |
NCT05717400CT.gov Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | — | Terminated | — | — | — |
NCT05211323CT.gov A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT05992220CT.gov Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion | — | Recruiting | — | — | — |
NCT05109052CT.gov Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT05411133CT.gov Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | — | Completed | — | — | — |
NCT02716012CT.gov First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Niek Wijnen | Approved | B · 62 |
| Dexmedetomidine | Uppsala University Hospital | P4 | BBB |
| Adriamycin | Shanghai Zhongshan Hospital | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Idarubicin | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Sorafenib | First Affiliated Hospital Xi'an Jiaotong University | P3 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Tranexamic Acid | Konkuk University Medical Center | P4 | BB |
+42 more in the Liver Cancer cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Liver Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-liver-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →